About this Journal Submit a Manuscript Table of Contents
ISRN Analytical Chemistry
Volume 2012 (2012), Article ID 135208, 4 pages
Research Article

Development and Validation of HPTLC Method for Estimation of Safinamide Mesylate in Bulk and in Tablet Dosage Form

Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education & Research, Dhule District, Shirpur 425 405, India

Received 1 January 2012; Accepted 14 February 2012

Academic Editors: G. Drochioiu, G. Erny, A. Jimenez, and G. Vecchio

Copyright © 2012 Vivekkumar K. Redasani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


A simple, specific, and precise high-performance thin-layer chromatographic method has been developed and validated for estimation of Safinamide Mesylate as bulk and in tablet dosage form. The chromatographic development was carried out on aluminum plates precoated with silica gel 60 F254 using a mixture of Toluene: Methanol: Triethylamine (4 : 1 : 0.5 v/v) as mobile phase. Detection was carried out densitometrically at 226 nm. The 𝑅 𝐹 value of drug was found to be 0 . 5 4 ± 0 . 0 2 . The method was validated with respect to linearity, accuracy, precision, and robustness. The calibration curve was found to be linear over a range of 400–2400 ng μL−1. The % assay (Mean ± S.D.) was found to be 1 0 0 . 2 7 ± 0 . 7 2 . Accuracy of the method was accessed by percentage recovery and found to be 9 9 . 7 7 ± 0 . 7 1 % . Thus the proposed HPTLC method was found to provide fast and cost-effective quantitative control for routine analysis of Safinamide mesylate as bulk and in tablet dosage form.

1. Introduction

Safinamide (SAF) is an orally available derivative from chemical class of 𝛼 -amino amides, with multiple mechanisms of action involving inhibition of mono-amino oxidase B and dopamine reuptake used in the treatment of epilepsy and parkinson’s disease. Chemically, Safinamide is ( 𝑆 )-(+)-2-[4-(3-fluorobenzyloxybenzylamino) propanamide] methane sulfonate (1 : 1 salt) (Figure 1) [1, 2].

Figure 1: Chemical structure of Safinamide Mesylate.

Literature survey reveals a validated chiral liquid chromatographic method for the enantiomeric separation of safinamide mesylate [3] and bioassay of safinamide in biological fluids of humans and various animal species [4].

Except this, so far no analytical method was available for estimation of SAF as indicated by detail literature survey. The therapeutic effectiveness and less methods available for its estimation encourage us to undertake this work, so that quantitative estimation of SAF can be done and hence can be used for routine analysis of bulk and formulation as well.

The present study describes the development and validation of a simple, specific, sensitive, accurate precise, and economic HPTLC method for determination of SAF in tablet dosage form. The proposed method is optimized and validated as per the International Conference on Harmonization (ICH) guidelines [5, 6].

2. Experimental

2.1. Chemicals and Reagents

Safinamide mesylate was kindly gifted from Alkem Pharmaceuticals, Mumbai (Maharashtra), India. Safinamide tablets were obtained from commercial sources within their shelf life period. All the reagents and solvents used were of analytical reagent (AR) grade. Solvents used like toluene, methanol, and triethylamine were of AR grade and obtained from Merck Chemicals.

2.2. Instrumentation and Chromatographic Conditions

The samples were spotted in the form of bands of width of 6 mm with a Camag 100 μL sample syringe (Hamilton, Bonaduz, Switzerland) on precoated silica gel aluminum plate 60 F254 ( 2 0 c m × 1 0 c m with 0.2 mm thickness) supplied by Anchrom technologists (Mumbai) using a CAMAG Linomat 5 sample applicator (Switzerland). A constant application rate of 200 nL sec−1 was employed, and the space between two bands was 15.4 mm. The slit dimension was kept 6 mm × 0.45 mm. The mobile phase consisted of toluene : methanol : triethylamine (4 : 1 : 0.5 v/v) was selected, which gave sharp and symmetrical peak with 𝑅 𝐹 0.54. The optimized chamber saturation time was 15 min at room temperature ( 2 5 C ± 2 C ) and relative humidity 6 0 % ± 5 % . The length of chromatogram run was approximately 8 cm. Subsequent to the development, TLC plates were dried with the help of an air dryer. Densitometric scanning was performed using Camag TLC scanner 3 equipped with win CATS software version 1.3.0 at 226 nm. The source of radiation utilized was deuterium lamp emitting a continuous UV spectrum in the range of 200–400 nm. Evaluation was performed using peak area with linear regression.

2.3. Preparation of Standard Stock Solution

An accurately weighed quantity of 10 mg SAF was transferred to 10 mL volumetric flasks, dissolved in methanol, and volume was made up to mark with the same solvent to obtain a working standard having concentration 1000 ng μL−1.

2.4. Optimization of HPTLC Method

Initially, different ratios of methanol, chloroform, n-propanol, and toluene were tried, but tailing of spots was observed. Finally, the mobile phase toluene:methanol:triethylamine (4 : 1 : 0.5% v/v) gives good resolution, sharp and symmetrical peak with 𝑅 𝐹 value of 0.54 at 226 nm (Figure 2).

Figure 2: Chromatogram of standard safinamide mesylate ( 𝑅 𝐹 0.54) measured at 226 nm.
2.5. Application of Proposed Method to Tablet Formulation

To determine the concentration of SAF in tablets (Label claim: 50 mg per tablet), the contents of 20 tablets were weighed, their mean weight determined, and were finely powdered. The powder equivalent to 10 mg of SAF was weighed. The drug from the powder was extracted with methanol. To ensure complete extraction of the drug, it was sonicated for 20 min and the volume was made up to 10 mL. The resulting solution was filtered using 0.41 μm filter (Millifilter, Milford, MA). The above solution was applied on TLC plate (1000 ng per spot) followed by development and scanning as described in above chromatographic conditions (Table 1).

Table 1: Analysis of Tablet formulation (Label claim: 50 mg per tablet).

3. Method Validation

The proposed method was validated as per the ICH guidelines in terms of its linearity, accuracy, specificity, intraday and interday precision, robustness, ruggedness, limit of detection (LOD), and limit of quantification (LOQ).

3.1. Linearity (Calibration Curve)

For linearity study, aliquots of 0.4, 0.8, 1.2, 1.6, 2.0, and 2.4 μL of SAF from standard stock solution was applied on TLC plate to obtain the concentration of 400, 800, 1200, 1600, 2000, and 2400 ng/band. TLC plates were developed under the above-established conditions. Area under peak was recorded and plotted against concentration (Figure 3).

Figure 3: Calibration curve for Safinamide mesylate in concentration 400–2400 ng/band.
3.2. Accuracy

The preanalyzed samples of concentration 1000 ng μL−1 were over spotted with excess 80, 100, and 120% of standard drug. The total concentrations of the drug was determined ( 𝑛 = 3 ), to check for the recovery of the drug at different levels in formulation.

3.3. Specificity

The specificity of the method was ascertained by analyzing standard drug and formulation. The spot for SAF in formulation was confirmed by comparing the 𝑅 𝐹 values and spectra of the spot with that of standard. The peak purity of SAF was assessed by comparing the spectra at three different levels, that is, peak start ( 𝑆 ), peak apex ( 𝑀 ), and peak end ( 𝐸 ) positions of the spot. A typical overlain spectrum of standard drug and drug extracted from tablet is shown in Figure 4.

Figure 4: A typical overlain spectrum of standard drug and drug extracted from tablet scanned at the peak-start, peak-apex, and peak-end positions of the band (Correlation > 0.99).
3.4. Precision

Repeatability was determined by spotting 1200 ng per spot of SAF. Precision of the method was assessed by spotting 800, 1200, and 1600 ng per spot of SAF on three different times within the same day (intraday) and on three different days (interday).

3.5. Robustness

Robustness of the method was performed by spotting 1200 ng of drug making small deliberate changes in various chromatographic conditions. Mobile phases having different composition of toluene : methanol : TEA (3.8 : 1.2 : 0.5 and 4.3 : 0.7 : 0.2 v/v) were tried, and chromatograms were run. The volume of mobile phase, temperature, and relative humidity was varied in the range of ± 5 % . The plates were prewashed by methanol and activated at 60 ± 5°C for 2, 5, and 7 min prior to chromatography. Time from spotting to chromatography and from chromatography to scanning was varied as 0, 20, and 40 min.

3.6. Ruggedness

Ruggedness of the method was performed by spotting 1200 ng of drug by two different analysts maintaining same experimental and environmental conditions.

3.7. Limit of Detection (LOD) and Limit of Quantification (LOQ)

In order to determine detection and quantification limit, concentrations in the lower part of the linear range of the calibration curve were used. SAF solutions of 400, 480, 560, 640, 720, and 800 ng μL−1 were prepared and applied in triplicate. The LOQ and LOD were calculated using equation L O D = 3 . 3 × 𝑁 / 𝐵 and L O Q = 1 0 × 𝑁 / 𝐵 , where 𝑁 is standard deviation of the peak areas of the drugs ( 𝑛 = 3 ), taken as a measure of noise, and 𝐵 is the slope of the corresponding calibration curve.

4. Results and Discussion

4.1. HPTLC Method Development

The TLC procedure was optimized with a view to develop a method for determination of SAF. Optimization of mobile phase with toluene : methanol : triethylamine (4 : 1 : 0.5) v/v gives sharp and symmetrical peak having 𝑅 𝐹 value of 0 . 5 4 ± 0 . 2 . It was observed that prewashing of TLC plates with methanol (followed by drying and activation) and presaturation of TLC chamber with mobile phase for 15 min ensures good reproducibility and peak shape.

4.2. Validation
4.2.1. Linearity

The linear regression data for the calibration curves showed good linear relationship over the concentration range 400–1200 ng μL−1. Linear regression equation was found to be 𝑌 = 2 . 4 7 4 𝑋 + 4 4 . 5 2 ( 𝑟 2 = 0 . 9 9 9 ) .

4.2.2. Accuracy

The proposed method when used for extraction and subsequent estimation of drug from tablet dosage form after over spotting with 80, 100, and 120% of additional drug; mean recovery is within acceptable limits, indicating the method is accurate and afforded recovery of 99.44–99.88% (Table 2).

Table 2: Results of recovery studies.
4.2.3. Specificity

The peak purity of SAF was assessed by comparing the spectra at three different levels, that is, peak start ( 𝑆 ), peak apex ( 𝑀 ), and peak end ( 𝐸 ) positions of the spot and the results obtained as 𝑟 2 ( 𝑆 , 𝑀 ) = 0 . 9 9 9 and 𝑟 2 ( 𝑀 , 𝐸 ) = 0 . 9 9 8 . Good correlation was obtained between standard and sample spectra of SAF.

4.2.4. Precision

The precision of the developed HPTLC method was expressed in terms of % RSD. The results depicted revealed high precision of the method (Table 3).

Table 3: Intraday and Interday Precision.
4.2.5. Robustness

The standard deviation of peak areas was calculated for each parameter, and % RSD was found to be less than 2% (Table 4).

Table 4: Robustness of the method.
4.2.6. Ruggedness

The % RSD was found to be less than 2% indicating the method was rugged when estimation was done by two different analysts, Table 5.

Table 5: Results of ruggedness study.
4.2.7. LOD and LOQ

Detection limit and quantification limit for SAF were found to be 13.09 ng and 39.67 ng, respectively. This indicates adequate sensitivity of the method as it can be validated in less quantity of drug, and hence the method proves to be economic.

5. Conclusion

The literature survey promoted us to develop HPTLC method on SAF as no analytical method was reported for it. The HPTLC method was developed and validated as per ICH guidelines, and the method was found to simple, precise, accurate reproducible, and economic, thus can be used for determination of SAF in tablets. Moreover, proposed method also indicates no interference of excipients when applied to tablet dosage form. Future plan includes development of Safinamide mesylate in available combinations along with stability-indicating and forced degradation-studies.


The authors are thankful to Alkem Pharmaceuticals Ltd. (Mumbai, Maharashtra) for providing a gift sample of Safinamide Mesylate.


  1. M. Onofrj, L. Bonanni, and A. Thomas, “An expert opinion on safinamide in Parkinson's disease,” Expert Opinion on Investigational Drugs, vol. 17, no. 7, pp. 1115–1125, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Marzo, L. Dal Bo, N. C. Monti et al., “Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity,” Pharmacological Research, vol. 50, no. 1, pp. 77–85, 2004. View at Publisher · View at Google Scholar
  3. K. Zhang, N. Xue, X. Shi, W. Liu, J. Meng, and Y. Du, “A validated chiral liquid chromatographic method for the enantiomeric separation of safinamide mesilate, a new anti-Parkinson drug,” Journal of Pharmaceutical and Biomedical Analysis, vol. 55, no. 1, pp. 220–224, 2011. View at Publisher · View at Google Scholar
  4. L. Dal Bo, P. Mazzucchelli, M. Fibbioli, and A. Marzo, “Bioassay of safinamide in biological fluids of humans and various animal species,” Drug Research, vol. 56, no. 12, pp. 814–819, 2006. View at Scopus
  5. ICH-Guidelines Q2A, “Validation of Analytical Procedures: Definition and terminology,” (CPMP III/5626/94), Geneva, Switzerland, 1995.
  6. ICH-Guidelines Q2B, “Validation of Analytical Procedures: Methodology,” (CPMP/ICH/281/95) Geneva, Switzerland 1996.